Literature DB >> 12464934

Molecular interactions between glucocorticoids and long-acting beta2-agonists.

Ian M Adcock1, Kittipong Maneechotesuwan, Omar Usmani.   

Abstract

beta(2)-Adrenergic receptor agonists and glucocorticoids are the two most effective treatments for asthma, and used in combination they are more effective than either alone. Glucocorticoids mediate their anti-inflammatory effects through the action of activated glucocorticoid receptors (GRs), with the level of activity being related to the number of nuclear receptors. Glucocorticoids can upregulate the synthesis of several genes in human lung cells through interaction with specific DNA binding regions (glucocorticoid response elements) within the promoter region of glucocorticoid-responsive genes. Many of the down-regulating effects of GRs on the synthesis of cytokines and other inflammatory mediators are due to repression of other transcription factors, such as activator protein-1 and nuclear factor kappaB. GR functions such as nuclear localization and gene activation can be regulated by phosphorylation status. Long-acting beta(2)-agonists may affect GR nuclear localization through modulation of GR phosphorylation and furthermore through priming of GR functions within the nucleus by modifying GR or GR-associated protein phosphorylation. Glucocorticoids in turn may regulate beta(2)-adrenergic receptor function by increasing its expression, acting through glucocorticoid response elements, and, importantly, by restoring G-protein-beta(2)-receptor coupling and inhibiting beta(2)-receptor downregulation, thereby preventing desensitization.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12464934     DOI: 10.1067/mai.2002.129705

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  14 in total

1.  The effect of inhaled budesonide and formoterol on bronchial remodeling and HRCT features in young asthmatics.

Authors:  Firuz Capraz; Erdogan Kunter; Hakan Cermik; Ahmet Ilvan; Suheyl Pocan
Journal:  Lung       Date:  2007-03-28       Impact factor: 2.584

Review 2.  Crosstalk in inflammation: the interplay of glucocorticoid receptor-based mechanisms and kinases and phosphatases.

Authors:  Ilse M E Beck; Wim Vanden Berghe; Linda Vermeulen; Keith R Yamamoto; Guy Haegeman; Karolien De Bosscher
Journal:  Endocr Rev       Date:  2009-11-04       Impact factor: 19.871

Review 3.  Long-acting beta2-agonists in asthma: not so SMART?

Authors:  Graeme P Currie; Daniel K C Lee; Brian J Lipworth
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 4.  Targeting key proximal drivers of type 2 inflammation in disease.

Authors:  Namita A Gandhi; Brandy L Bennett; Neil M H Graham; Gianluca Pirozzi; Neil Stahl; George D Yancopoulos
Journal:  Nat Rev Drug Discov       Date:  2015-10-16       Impact factor: 84.694

5.  From Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines to current clinical practice : an overview of the pharmacological therapy of stable chronic obstructive pulmonary disorder.

Authors:  Raffaele Antonelli Incalzi; Andrea Corsonello; Claudio Pedone; Giulio Masotti; Vincenzo Bellia; Vittorio Grassi; Franco Rengo
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

6.  Human tau may modify glucocorticoids-mediated regulation of cAMP-dependent kinase and phosphorylated cAMP response element binding protein.

Authors:  Yudong Liu; Ying Su; Shenggang Sun; Tao Wang; Xian Qiao; Hui Li; Xiaoqin Run; Zhihou Liang
Journal:  Neurochem Res       Date:  2012-05       Impact factor: 3.996

7.  The synergistic anti-asthmatic effects of glycyrrhizin and salbutamol.

Authors:  Yang Yang; Qian Shi; Ze Liu; Ruo-jie Li; Peng-wei Pan; Yuan-yuan Hou; Wan-ge Lu; Gang Bai
Journal:  Acta Pharmacol Sin       Date:  2010-03-15       Impact factor: 6.150

Review 8.  Routine Use of Budesonide/Formoterol Fixed Dose Combination in Elderly Asthmatic Patients: Practical Considerations.

Authors:  Nicola Scichilone; Fulvio Braido; Federico Lavorini; Mark L Levy; Omar S Usmani
Journal:  Drugs Aging       Date:  2017-05       Impact factor: 3.923

9.  Cost-effectiveness of combination therapy for chronic obstructive pulmonary disease.

Authors:  Anderson Chuck; Philip Jacobs; Irvin Mayers; Darcy Marciniuk
Journal:  Can Respir J       Date:  2008 Nov-Dec       Impact factor: 2.409

10.  Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial.

Authors:  Jean Bourbeau; Pota Christodoulopoulos; Francois Maltais; Yasuhiro Yamauchi; Ronald Olivenstein; Qutayba Hamid
Journal:  Thorax       Date:  2007-06-08       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.